Celiac Disease and the Autoimmune Web of Endocrinopathies

Ibrahim Sange 1, Mohamed Wael F. Mohamed 2, Su Aung 3, 4, Nakul Mereddy 4, Pousette Hamid 5

1. Medicine, K. J. Somaiya Medical College and Research Centre, Mumbai, IND
2. Neurological Surgery, The Royal London Hospital, London, GBR
3. Medicine/Surgery, University of Medicine, Yangon, MMR
4. Neurosciences, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
5. Neurology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA

Corresponding author: Ibrahim Sange, ibulicious9955@gmail.com

Abstract

Gluten-sensitive enteropathy or Celiac disease (CD) is a disease that has become very prevalent in most parts of the globe especially in the western world. Resulting from a chaotic interplay between the backgrounds of autoimmunity and genetics, this disorder targets primarily the gastrointestinal tract with ominous extraintestinal counterparts that have a very discrete presentation. Among those counterparts, the one that has been reviewed in this article is the involvement of the endocrine system as concurrence of hormonal disorders with CD possesses numerous challenges that lead to a refractory treatment and a dull prognosis. This review article aims to feature the effect of the CD and endocrine disorders on one another, especially if either of the diseases is asymptomatic, explore the clinical dilemma faced by clinicians in various specialties, and, hence, further pave a path into the importance of rigorous screening and diagnosis.

Categories: Endocrinology/Diabetes/Metabolism, Internal Medicine, Gastroenterology
Keywords: celiac disease, celiac disease and autoimmunity, celiac disease and endocrine system, celiac disease and thyroid, celiac disease and diabetes, celiac disease and glandular autoimmunity

Introduction And Background

Celiac disease (CD) is an autoimmune disorder of the gastrointestinal tract that occurs in genetically predisposed patients in response to gluten-containing food such as wheat, rye, and barley [1]. In the western population, serological studies were conclusive of a prevalence of almost 1% with a major chunk of the disease population still being undiagnosed [1,2].

In addition to the environmental factors like viral infections and gut microbiota dysbiosis, an obligatory genetic association remains that of the linkage of the disease to human leukocyte antigen (HLA) DQ2/DQ8 [3]. With a minor female predominance, the disease occurs irrespective of age and with a multitude of phenotypes - gastrointestinal, extraintestinal, subclinical, potential, seronegative, non-responsive, and refractory [3]. Although small intestinal biopsy is still being considered as the gold standard for the diagnosis of the disease, there is satisfactory upcoming evidence of serological autoantibodies such as anti-gliadin antibodies, anti-deamidated gliadin peptide antibodies, anti-tissue transglutaminase (anti-tTG) antibodies, and anti-endomysial (anti-EMA) antibodies in aiding in the screening of the disease as they have a superior margin of sensitivity and specificity [4]. There have been multiple approaches and modalities of treatment over the years, but a gluten-free diet is the only primary intervention that has successfully prevented the current manifestations as well as slowed the progression of the disease.

The insidious coexistence of endocrine diseases has been well documented and demonstrated in patients with CD. The common autoimmune background and a moderate overlap of symptoms and signs serve a grim prognosis and a stubborn outcome of treatment. There have been ample amount of studies that have illustrated the increased prevalence of endocrine conditions with a peculiar emphasis on type 1 diabetes mellitus (DM) and autoimmune thyroid conditions [5,6]. Other rare endocrine associations like adrenal insufficiency, hypoparathyroidism, infertility, and pituitary involvement have also been noted [7-10].

This article aims to:

1. Underline the growing concern of the endocrinopathies that are masked by the veil of CD due to the heterogeneity in its clinical presentation and the delay in the diagnosis of the disease itself.
2. Highlight the impact of CD on the endocrine system with an attempt to unravel the silent systemic autoimmune clinical impact of the coexistence of the disorders.
3. Vocalize the possibilities and advantages of screening, early diagnosis, and treatment for these conditions.
Review

Methods

A robust search performed on databases including PubMed and PubMed Central was conducted where only peer-reviewed articles published from 1990 to 2020 in English language and relevant to the topic were included. The following are the inclusion/exclusion criteria that were applied:

1. Studies of all designs/types were included, and gray literature was excluded.
2. Although all age groups were included, a particular emphasis was placed on the pediatric and adult age group.
3. Studies performed globally irrespective of ethnicities and geography were included.
4. Studies done only on humans were included, and the rest were excluded.

Diabetes and CD

When it comes down to the basic pathophysiologic development of the disease, CD and type 1 DM share a common basis of autoimmunity where there is a development of antibodies that lead to the clinical progression of the diseases. Type 1 DM is a heterogeneous autoimmune disorder confined usually to the young population, where there are antibodies against the beta islet cells of the pancreas causing their destruction leading to a profound state of insulin deficiency and uncontrolled hyperglycemia. CD is one of the few autoimmune disorders, which has a very obscure primary trigger and is turned around with just avoidance of the causative agent. Over the course of time, the prevalence of coexistence of CD and type 1 DM has been well documented by numerous studies conducted across various parts of the globe [11,12].

There were several factors in motion as to why the incidence of CD and type 1 DM was lesser compared to what it is today. First, very little was known about both the diseases a long time ago in terms of their pathogenesis and trajectory of progression. Second, a distinct overlap in certain symptoms and signs such as diarrhea and weight loss that occurred in both the conditions could not be differentiated and narrowed upon. Currently, we stand on a very high pedestal in terms of the knowledge of the diseases, their respective screening processes, their individualized management, and also decoding of their non-classical presentations.

The genetic basis of the two diseases anchors itself on certain observations made such as the following:

1. Identical twins had almost a 50% and 75% chance of developing type 1 DM and CD, respectively, compared to the general population [5].
2. First-degree relatives had an increased risk of developing both the disorders compared to the general population [5,13].

The concept of linkage disequilibrium comes into play in this scenario where the sharing of HLA, specifically DR3 and DQ2, is evidently exhibited by both these conditions [14].

A study was conducted over a period of 19 years in Australia in a sample population of 4379 children below the age of 18 years, who were regularly followed up and subsequently categorized in different subsets with respect to their age. It was found that CD was diagnosed in diabetics at a percentage of 45, 78, and 95 at two, five, and 10 years of age, respectively. The study also concluded that children with type 1 DM onset at an age less than five years were at a greater risk of developing CD, thereby establishing a directly proportional relationship between the duration of insulin deficiency and that of gluten sensitivity [15] (Table 1).
In a retrospective hospital record-based cohort study performed on a group of children in Saudi Arabia, out of 430 cases of type 1 DM, 48 cases of CD were diagnosed. The study rested upon the conclusion that there was an increased prevalence of CD in patients with type 1 DM [16] (Table 1).

A peculiar finding was noted in a longitudinal cross-sectional study performed in Italy where it was discovered that patients underwent seroconversion with respect to CD after an average period of 18 months, suggesting a temporal relationship between the diseases and also raising thoughts about viral infections and environmental factors playing either an individualized or a combined role in serving as the trigger factor for both the conditions [17] (Table 1).

The findings of the above studies can be compared in parallel to another study that was conducted in Italy in the pediatric age group where 4322 diagnosed cases of DM were screened for the presence of CD. There were 292 cases of the biopsy-proven CD out of the entire sample population taken into consideration. This study too was conclusive of the fact that there was an increased prevalence of CD in patients with type 1 DM, and the coexistence of these diseases grew with an earlier onset of type 1 DM. Additionally, a noteworthy conclusion of a slightly higher female predominance was also made at the end of the study [18] (Table 1).

The co-occurrence of the two conditions warrants a strict screening protocol that has been implemented by the American Diabetes Association [19]. The screening is to be done by checking for the presence of

1. anti-tTG IgA antibodies,
2. anti-endomysial (anti-EMA) antibodies, and
3. anti-tTG IgG antibodies, if there is presence of IgA deficiency in the patient.

The guidelines are along the lines of the following [19]:

1. CD should be screened soon after type 1 DM is diagnosed and if negative to be followed up after two and five years.
2. Patients with type 1 DM exhibiting symptoms of CD should be screened as soon as possible irrespective of a previous negative result.

A multi-directional approach should be engineered toward the management of these two conditions keeping in mind the common background and the development of complications. Therefore, a gluten-free diet balanced by a properly tailored insulin regimen will help achieve a desirable blood glucose level and prevent malabsorption, thereby constructing an optimistic tangent to the prognosis of the patient.

### TABLE 1: Summary of included studies linking celiac disease and type 1 diabetes mellitus.

| References          | Design                                  | Cases of DM | Cases of CD | Population                        | Diagnostic criteria                                                                 | Conclusion                                                                 |
|---------------------|-----------------------------------------|-------------|-------------|-----------------------------------|-------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Pham-short et al.   | Observational cohort study              | 4379        | 185         | Children < 18 years from Australia| For CD – anti-tTG, anti-EMA antibodies, and small intestinal biopsy                  | CD was strongly associated with type 1 DM and was directly related to an earlier age of onset and a longer duration of the disease. |
| Saadah et al.       | Retrospective hospital record-based study| 430         | 48          | Children in Saudi Arabia          | For CD – anti-tTG and small intestinal biopsy                                       | Increased prevalence of CD in patients with type 1 DM                      |
| Salardi et al.      | Longitudinal cross-sectional study      | 331         | 22          | Children in Italy                 | For CD – anti-EMA antibodies                                                         | Increased risk of CD in type 1 DM, which was triggered by environmental and infectious etiologies |
| Cerutti et al.      | Cohort study                            | 4322        | 292         | Children in Italy                 | For CD – anti-tTG, anti-EMA antibodies, and small intestinal biopsy                  | CD was strongly associated with type 1 DM and was directly related to an earlier age of onset and a slight female predominance. |

Anti-tTG, Anti-tissue transglutaminase; anti-EMA, anti-endomysial antibody; CD, Celiac disease; DM, diabetes mellitus.
CD and thyroid

When the thyroid gland is referred to with the context of autoimmunity, there are two prominent disorders that come up - Hashimoto’s thyroiditis and Graves’ disease. Hashimoto’s thyroiditis is a diversified autoimmune disorder where the presence of anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin antibodies dial the functioning of the thyroid gland causing transient hyperthyroidism and eventual hypothyroidism. Graves’ disease on the other hand is a type two hypersensitivity reaction where there are IgG thyroid-stimulating globulins, which lead to a state of thyrotoxicosis.

The eventual linkage between CD and autoimmune thyroiditis stems from certain hypothesized theories:

1. Similarly as in the case of type 1 DM, CD and autoimmune thyroiditis are linked by the fabric of HLA subtypes: HLA-DQ2, HLA-DR3, and B8. This varies largely between individuals and is more of a consequence of the multifactorial genetic inheritance [20,21].

2. Thyroid gland is differentiated from the pharyngeal gut sharing a common origin [21].

3. Increased penetration of the intestine leads to humongous amounts of precursor antigens in the bloodstream, which leads to a cross-reaction elsewhere in the body [22].

4. Tissue transglutaminase cross-reacts directly with the thyroid gland [23].

A cross-sectional screening study performed on a group of 12-year-old children from Sweden demonstrated a threefold increase in the presence of thyroid antibodies in cases diagnosed with CD [24] (Table 2).

| References               | Design        | Cases                  | Control Population          | Diagnostic criteria                                                                 | Conclusion                                  |
|--------------------------|---------------|------------------------|----------------------------|--------------------------------------------------------------------------------------|---------------------------------------------|
| Van der Pals et al. (2014) [24] | Cross-sectional | 335 cases of CD out of 12632 children | -                          | For CD – anti-tTG, anti-EMA antibodies, and small intestinal biopsy. For thyroid disease – anti-TPO antibodies | Increased prevalence of thyroid disease in patients with CD |
| Meloni et al. (2007) [25]  | Case-control  | 324 cases of CD       | 8040, age matched          | For CD – small bowel biopsy. For thyroid disease – FT4, FT3, TSH, USG, and anti-TPO antibodies | Increased association of autoimmune thyroid conditions with CD |
| Kowalska et al. (2000) [26] | Case-control  | 34 cases of CD        | 28 with negative screening for CD | For CD – anti-EMA antibodies. For thyroid disease – FT4, FT3, TSH, anti-ATG, and anti-TPO antibodies | Increased prevalence of thyroid antibodies in patients with CD |
| Velluzzi et al. (1998) [27] | Case-control  | 47 cases of CD        | 91 healthy controls        | Adult population from Sardinia, Italy. For CD – anti-tTG, anti-ARA antibodies, anti-EMA antibodies, and small intestinal biopsy. For thyroid disease – FT4, FT3, TSH, and anti-TPO antibodies | Increased prevalence of thyroid antibodies in patients with CD |

**TABLE 2: Summary of included studies linking celiac disease and thyroid diseases.**

Anti-tTG, anti-tissue transglutaminase; anti-EMA, anti-endomysial antibodies; CD, Celiac disease; DM, diabetes mellitus; FT4, FT3, free T4, free T3; TSH, thyroid-stimulating hormone; anti-ATG, anti-thymocyte globulin; anti-TPO antibodies, anti-thyroid peroxidase antibodies; anti-ARA, anti-reticulin antibodies.

A case-control study was performed in 2007 on a subgroup of children in Sardinia, Italy, where 8040 controls were considered alongside 324 cases of CD who were then subsequently screened, and there was an increased incidence of autoimmune thyroiditis in the patients with CD [25] (Table 2).

Another case-control study was performed in 2000 in a sample population of children where there were 34 cases matched with 28 controls. The study arrived at a conclusion of the presence of thyroid antibodies in the cases with a measure of 41.1% in comparison to the control group where the measure was 3.56% [26] (Table 2).

This could be aligned with a similar case-control study that was performed in 1998 on a subgroup of adult
population in Sardinia, Italy, where 91 healthy controls were selected besides 47 cases having CD. The patients were screened and were found to have an increased prevalence of thyroid autoimmunity. A fascinating observation made in these patients was that of the presence of the DQB1*0502 genotype [27] (Table 2).

An evaluation of 111 patients with Graves’ disease at a thyroid clinic with healthy age-matched controls in the local population yielded an inference of the presence of CD in these patients of about 4.5% compared to that of 0.9% in healthy controls. An important highlight of this study was that the screening process leads to the diagnosis of three new cases of CD [28].

The reason clinicians often arrive at crossroads along the course of diagnosis is due to the synonymous symptomatology that occurs [21] (Figure 1):

1. The intestinal motility is a function of several hormones including the thyroid hormone, and hence diarrhea that occurs in CD can be variable depending upon the thyroid status.
2. Weight loss is a feature shared by CD as well as hyperthyroidism.
3. Malabsorption in CD can hinder the absorption of thyroid medications.
4. Menstrual cycle abnormalities can present themselves in rare cases in CD and is much more common in thyroid diseases.
5. Osteoporosis can present itself in CD and hyperthyroidism, both.

A very compelling rare occurrence of thyroid lymphoma as an extranodal complication of CD has also been recognized [29]. This in turn again reflects on the theory of the common embryologic origin of the thyroid and the primitive gut.

The point that has to be emphasized here is to screen all the patients with CD for the presence of thyroid autoimmunity and vice versa. A gluten-free diet has been argued considerably to single-handedly untangle the above-mentioned cobwebs created by the coexistence of these two diseases [30,31].

**CD and other endocrine glands**

Although the thyroid and the pancreas are the two most common glands involved in association with CD, there are very rare forms of endocrinopathies that have to be appreciated.

Adrenal insufficiency linked to CD has been reported in certain studies and case reports. A Swedish study.
was conducted where 14,366 cases of CD were identified through the national registry. After matching 70,095 references with the corresponding variables, it was found that there existed a temporal relationship between these two diseases, thereby testifying to the correlation between the two diseases [7]. Screening for CD is highly advised if a patient presents with adrenal insufficiency especially to the cases that are refractory to treatment.

The parathyroid gland works in close harmony with the gastrointestinal tract, kidneys, and bones to maintain adequate calcium balance in the body. Due to the villous atrophy that occurs in CD, there is decreased absorption of calcium and vitamin D along the gastrointestinal tract, which naturally leads to decreased calcium levels in the serum and therefore leading to secondary hyperparathyroidism. After a long deceitful period, the bone gradually loses the calcium and eventually weakens over time leading to osteoporosis due to which the patient presents with symptoms of bone pain, fatigue, etc. In a study conducted with 66 cases of CD and 76 healthy controls, patients with a longer duration of CD were more vulnerable to osteoporosis compared to the ones that were diagnosed earlier and the controls. The study also deduced that a gluten-free diet was necessary for children to achieve adequate bone mineralization [32]. Although as explained above, secondary hyperparathyroidism is relatively a common occurrence among patients with CD. Hypoparathyroidism is a much more isolated disease that occurs in relation to CD. There have been case reports suggesting the coexistence of these two conditions based on their customary autoimmune framework, but improvement was noted on adherence to a gluten-free diet [8,33].

Development of antibodies against the pituitary gland was well demonstrated in a cross-sectional study that was conducted in Italy, in which out of 119 patients diagnosed with CD, 50 patients were found to have pituitary antibodies as further investigations unfurled [10]. The implications of the resultant damage to the pituitary gland could be catastrophic in terms of stunted growth, hypogonadism, and prolactin imbalances.

Ovarian failure and infertility can sometimes be masked by the blanket of subclinical CD resulting in menstrual irregularities and premature menopause. There have been studies that have very clearly harbored a correlation between these two conditions with infertility affecting not only women but also men [34,35].

Conclusions

Despite CD presenting with predominant gastrointestinal involvement, there is a very complex and diverse extraintestinal involvement that can make the diagnosis cumbersome. The main point to be highlighted in this article is to see the CD from a multi-system perspective and orchestrate a multicentered approach toward the disease rather than just looking at it from one standpoint. As this article primarily focused on the endocrine involvement, it is important to realize that the limited prevalence of the simultaneous presence of these disorders leads to restricted documentation of these illnesses leaving most aspects of these diseases undiagnosed. This can be rectified by a stringent screening protocol along with wide availability of screening tools, and widespread awareness of these silent yet easily treatable disorders will propel the patient into a land of promising recovery and a long-term favorable prognosis.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Fasano A, Berti L, Gerarduzzi T, et al.: Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med. 2005, 165:286-92. 10.1001/archinte.165.3.286
2. Mustalathi K, Catassi C, Reunanen A, et al.: The prevalence of celiac disease in Europe: results of a centralized, international mass screening project. Ann Med. 2010, 42:587-95. 10.3109/07853890.2010.505931
3. Caio G, Volta U, Sapone A, Lefter DA, De Giorgio R, Catassi C, Fasano A: Celiac disease: a comprehensive current review. BMC Med. 2019, 17:142. 10.1186/s12916-019-1580-z
4. Freeman HJ: Detection of adult celiac disease with duodenal screening biopsies over a 30-year period. Can J Gastroenterol. 2015, 27:405-8. 10.1155/2013/347902
5. Hagopian W, Lee HS, Liu E, et al.: Co-occurrence of type 1 diabetes and celiac disease autoimmunity. Pediatrics. 2017, 140:20171305. 10.1542/peds.2017-1305
6. Ching CL, Jones MK, Kingham JGC: Celiac disease and autoimmune thyroid disease. Clin Med Res. 2007, 5:184-192. 10.5121/cmr.2007.738
7. Elfström P, Montgomery SM, Kämpe Ö, Ekborn A, Ludvigsson JF: Risk of primary adrenal insufficiency in patients with celiac disease. J Clin Endocrinol Metab. 2007, 92:3595-8. 10.1210/jc.2007-0960
8. Matsueda K, Rosenberg IH: Malabsorption with idiopathic hypoparathyroidism responding to treatment for coincident celiac sprue. Dig Dis Sci. 1982, 27:269-273. 10.1007/BF01296927

9. Khizroeva J, Nalli C, Bitsadze V, et al.: Infertility in women with systemic autoimmune diseases. Best Pract Res Clin Endocrinol Metab. 2019, 33:101369. 10.1016/j.bepem.2019.101369

10. Delvecchio M, De Bellis A, Franchi R, et al.: Anti-pituitary antibodies in children with newly diagnosed celiac disease: a novel finding contributing to linear growth impairment. Am J Gastroenterol. 2010, 105:691-696. 10.1038/ajg.2009.642

11. Fraser-Reynolds KA, Butzen JD, Stephure DK, Trussell RA, Scott RB: Use of immunoglobulin A antiendomysial antibody to screen for celiac disease in North American children with type 1 diabetes. Diabetes Care. 1998, 21:1985-9. 10.2337/diabetes.41.12.1985

12. Mäki M, Huoponen T, Holm K, Hällström Ö: Sensitization of reticulin autoantibodies predicts celiac disease in insulin dependent diabetes mellitus. Gut. 1995, 36:239-42. 10.1136/gut.36.2.239

13. Winkel C, Jolink M, Knopff A, Kwarteng NA, Achenbach P, Bonifacio E, Ziegler AG: Age, HLA, and sex define a marked risk of organ-specific autoimmunity in first-degree relatives of patients with type 1 diabetes. Diabetes Care. 2019, 42:1684-1691. 10.2337/dc19-0315

14. Lie BA, Sollid LM, Ascher R, et al.: A gene telomeric of the HLA class I region is involved in predisposition to both type 1 diabetes and celiac disease. Tissue Antigens. 1999, 54:162-8.

15. Pham-Short A, Donaghue KC, Ambler G, Chan AK, Craig ME: Celiac disease in type 1 diabetes from 1990 to 2009: higher incidence in young children after longer diabetes duration. Diabet Med. 2002, 29:286-9.

16. Saadah OI, Al-Agha AE, Nahdi HMA, Bokhari RY, Talib YYB, Al-Mughaleh JA, Bokhari SMA: Prevalence of celiac disease in children with type 1 diabetes mellitus screened by anti-tissue transglutaminase antibody from Western Saudi Arabia. Saudi Med J. 2012, 33:541-6.

17. Salardi S, Volta U, Zucchini S, Fiorini E, Maltoni G, Vaira B, Cicognani A: Prevalence of celiac disease in children with type 1 diabetes mellitus increased in the mid-1990s: an 18-year longitudinal study based on anti-endomysial antibodies. J Pediatr Gastroenterol Nutr. 2008, 46:612-614. 10.1097/MPG.0b013e31815d697e

18. Cerutti F, Bruno G, Chiarelli F, et al.: Younger age at onset and sex predict celiac disease in children and adolescents with type 1 diabetes: an Italian multicenter study. Diabetes Care. 2004, 27:1294-8.

19. 10.2337/diabetes.2004.27.6.1294

20. Goodwin G: Type 1 diabetes mellitus and celiac disease: distinct autoimmune disorders that share common pathogenic mechanisms. Horm Res Paediatr. 2019, 92:285-292. 10.1159/0005053142

21. Badenhoop K, Dieterich W, Segni M, et al.: HLA DQ2 and/or DQ8 is associated with celiac disease-specific autoantibodies to tissue transglutaminase in families with thyroid autoimmunity. Am J Gastroenterol. 2001, 96:1648-9.

22. Khater D: Endocrinopathies in celiac disease: when the endocrinologist sees what is invisible to the gastroenterologist. Acta Biomed. 2018, 89:117-121. 10.23750/abm.v89i1.7119

23. Larizza D, Calcaterra V, De Giacomo C, et al.: Celiac disease in children with autoimmune thyroid disease. J Pediatr. 2009, 155:738-40. 10.1067/mpd.2001.118189

24. Naier AJ, Shah J, Hernandez L, et al.: Tissue transglutaminase antibodies in individuals with celiac disease bind to thyroid follicles and extracellular matrix and may contribute to thyroid dysfunction. Thyroid. 2008, 18:1171-8. 10.1089/thy.2008.0110

25. van der Pals M, Ivanovs A, Norström F, Högberg L, Svensson J, Carlsson A: Prevalence of thyroid autoimmunity in children with type 1 diabetes mellitus and effect of gluten withdrawal: an Italian multicenter study. Am J Gastroenterol. 2019, 114:4155-6. 10.1111/ajg.15756

26. Meloni A, Mandas C, Jores RD, Congia M: Prevalence of autoimmune thyroiditis in children with celiac disease and effect of gluten withdrawal. J Pediatr. 2009, 155:51-5. 10.1016/j.jpeds.2009.01.013

27. Kowalcza E, Wozniak-Krol-Kowalska E, Toporowska-Kowalska E: Estimation of anti-thyroid antibodies occurrence in children with celiac disease. Med Sci Monit. 2010, 6:1719-21.

28. Velluzi F, Caradonna A, Boy M, et al.: Thyroid and celiac disease: clinical, serological, and echographic study. Am J Gastroenterol. 1998, 93:976-979.

29. Ch'ng CL, Biswas M, Benton A, Jones MK, Kingham JGC: Prospective screening for celiac disease in patients with Graves' hyperthyroidism using anti-gliadin and tissue transglutaminase antibodies. Clin Endocrinol (Oxf). 2005, 62:305-6. 10.1111/j.1365-2265.2005.02214.x

30. Freeman HI: T cell lymphoma of the thyroid gland in celiac disease. J Pediatr Gastroenterol. 2000, 30:635-6.

31. 10.1155/2000/58326a

32. Sategna-Guidetti C, Volta U, Ciacci C, et al.: Prevalence of thyroid disorders in untreated adult celiac disease patients and effect of gluten withdrawal: an Italian multicenter study. Am J Gastroenterol. 2001, 96:751-7.

33. 10.1550/EC-16-0021

34. Scotton SM, Salvatore S, Salvatoni A, Del Giacomo C, Di Calcaterra V, De Giacomo C, Sategna-Guidetti C: Hypoparathyroidism and hypothyroidism: a complex disease. Clin Endocrinol (Oxf). 2003, 59:197-201. 10.1046/j.1365-2265.2002.02625.x

35. Karaca N, Yilmaz R, Aktun LJH, Batmaz G, Karaca C: Use of thyroid function tests and antithyroid antibodies in children with celiac disease. J Pediatr Gastroenterol Nutr. 2004, 39:117-21. 10.1097/00050571-200409001-00001

36. Singh P, Arora S, Lal S, Strand T, Makkar GA: Celiac disease in women with infertility: a meta-analysis. J Clin Gastroenterol. 2016, 50:55-59. 10.1097/MCG.0000000000002685